HIV Vpu

HIV Vpu Full Name

Human Immunodeficiency Virus Viral Protein U

HIV Vpu Introduction

HIV-1 Vpu is a multifunctional accessory protein that enhances viral replication and spread through several complementary mechanisms. Its most critical activity is antagonism of the host restriction factor BST-2/tetherin, which normally prevents release of budding virions by tethering them to the cell surface. Vpu interacts directly with tetherin, promoting its mislocalization and degradation—often via β-TrCP–dependent pathways—thereby enabling efficient virion release. This tetherin antagonism is especially potent in HIV-1 group M Vpu proteins, which likely contributed to the global pandemic spread of group M viruses. In contrast, Vpu proteins from groups N, O, and P frequently show reduced or absent anti-tetherin activity, consistent with their more limited epidemiological distribution. Mutational and pharmacologic studies further demonstrate that disrupting the Vpu–BST-2 interface can inhibit viral release, highlighting this interaction as a potential therapeutic target.

Beyond tetherin antagonism, Vpu performs additional functions that optimize viral replication and immune evasion. One conserved activity is downregulation of CD4 in the endoplasmic reticulum through β-TrCP–dependent ubiquitin-proteasome pathways. By reducing surface CD4 expression, Vpu facilitates virion release and prevents CD4-mediated interference with Env incorporation or superinfection. Vpu also modulates immune signaling pathways, including inhibition of NF-κB activation and downregulation of immune receptors such as NTB-A, which can dampen natural killer cell–mediated cytotoxicity. These activities illustrate that Vpu acts as a multifunctional regulator, coordinating viral assembly with evasion of host immune responses. However, the strength of these functions varies among natural Vpu alleles and subtypes, indicating functional diversity that may influence viral fitness and pathogenesis.

Evolutionary and translational analyses underscore the importance of Vpu functional variation. Group M Vpu proteins generally possess robust tetherin antagonism and CD4 downregulation capabilities, whereas non-M groups often lack efficient anti-tetherin activity, aligning with their restricted spread. Within group M, subtype-specific differences in Vpu function have been documented, with some subtypes exhibiting weaker tetherin antagonism or variable CD4 downregulation. These phenotypic differences may influence transmission dynamics and disease progression. From a therapeutic perspective, targeting the Vpu–BST-2 interaction or stabilizing tetherin at the cell surface could suppress viral release and complement existing antiretroviral strategies. Nevertheless, because Vpu also regulates immune signaling and viral assembly, interventions must consider potential downstream effects. Overall, Vpu exemplifies how a small accessory protein integrates multiple molecular functions to enhance HIV replication and persistence, making it an important subject for ongoing research in virology and therapeutic development.

Alternate Names for HIV Vpu

Human immunodeficiency virus; HIV; Human immunodeficiency virus 1; Lentivirus; Retroviridae; Vpu; Viral Protein U; Vpu protein

• 1. Renga F., et al. The HIV Matrix Protein p17 Promotes the Activation of Human Hepatic Stellate Cells through Interactions with CXCR2 and Syndecan-2. PLOS ONE. 2014;9(9):e94798.
  2. Caccuri M., et al. Cellular aspartic proteases promote the unconventional secretion of biologically active HIV-1 matrix protein p17. Scientific Reports. 2016;6:38027.
  3. D'Ursi A., et al. Molecular Mechanisms Involved in the B Cell Growth and Clonogenic Activity of HIV-1 Matrix Protein p17 Variants. Viruses. 2024;16(7):108.
  4. Caccuri M., et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proceedings of the National Academy of Sciences. 2012;109(30):11476–11481.